Acura Pharmaceuticals (ACUR) News

Acura Pharmaceuticals (ACUR): $0.07

-0.03 (-30.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ACUR News Items

ACUR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ACUR News From Around the Web

Below are the latest news stories about Acura Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACUR as an investment opportunity.

Acura, Abuse Deterrent Pharmaceuticals amend license deal for pain drug LIMITx LTX-03

Acura Pharmaceuticals (ACUR) amended a license, development and commercialization agreement for its product candidate LIMITx LTX-03 with Abuse Deterrent Pharmaceuticals to extend the…

Seeking Alpha | March 1, 2022

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

Amendment Extends NDA Acceptance DatePALATINE, Ill., March 01, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to December 31, 2022. The Company expects to complete clinical studies and other required s

Yahoo | March 1, 2022

Acura Pharmaceuticals Provides Development Update on LTX-03

PALATINE, Ill., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patente

Yahoo | February 14, 2022

Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Pass Above 200 Day Moving Average of $0.55

Shares of Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.55 and traded as high as $0.55. Acura Pharmaceuticals shares last traded at $0.55, with a volume of 2,404 shares traded. The company has a quick ratio of 0.86, a []

Dakota Financial News | December 11, 2021

Acura Pharmaceuticals reports Q3 results

No summary available.

Seeking Alpha | November 15, 2021

Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results

PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021.

Intrado Digital Media | November 15, 2021

Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results

PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021. The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for th

Yahoo | November 15, 2021

Acura Pharmaceuticals (OTCMKTS:ACUR) Stock Crosses Above 200-Day Moving Average of $0.52

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR)s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.52 and traded as high as $0.56. Acura Pharmaceuticals shares last traded at $0.56, with a volume of 12,403 shares changing hands. The stock has a market capitalization of $12.38 []

Dakota Financial News | November 10, 2021

Acura Pharmaceuticals reports Q2 results

No summary available.

Seeking Alpha | August 16, 2021

Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results

PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021.

Intrado Digital Media | August 16, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5111 seconds.